Natural Product (NP) Details
General Information of the NP (ID: NP6054) | |||||
---|---|---|---|---|---|
Name |
Selenium
|
||||
Synonyms |
7782-49-2; Se; Selenium; SELENIUM ATOM; Selenium and compounds; Elemental selenium; Selenium elemental; Selenium, elemental; Selen; SELENIUM COMPOUNDS; Selenium dihydride; SELENIUM POWDER; Hydrogen selenide (H2Se); UNII-H6241UJ22B; MFCD00134090; UNII-V91P54KPAM; H6241UJ22B; Vandex; Gray selenium; Selenium alloy; Selenium base; Selenium dust; Selenium, 99+%, powder; Colloidal selenium; Selen [Polish]; Selenium, metallic; Selenium homopolymer; Selenium, colloidal; Caswell No. 732; selenio; Selenium anhydride; Electronic E-2; Selenium metallicum; Selenium, 99.5+%, powder, 200 mesh; CCRIS 4250; HSDB 4493; EINECS 231-957-4; UN2658; EPA Pesticide Chemical Code 072001; Selenium compounds, n.o.s.; CI 77805; Selenium standard solution, for AAS, 1 mg-ml Se in 10% HCl; Selenium and selenium compounds; HSDB 548; C.I. 77805; Selenium, powder; EINECS 231-978-9; Selenium shot, 4N; UN2202; UN3283; ACMC-20ajqt; Dihydrogen monoselenide; selenium (iv) hydride; Selenium hydride (SeH2); 34Se; EC 231-957-4; Selenium, powder, 99+%; Selenium compound, n.o.s.; Hydrogen selenide, anhydrous; Selenium powder, -200 mesh; Selenium powder, -325 mesh; Selenium, p.a., 99.5%; CHEMBL1235891; DTXSID9021261; CHEBI:27568; HSDB 6909; DTXSID20872822; Selenium Nanopowder in aq. media; 8988AF; MFCD00011224; DB11135; Selenium, pellets, < 5mm, >=99.999%; FT-0701285; Selenium ingot/button, ~38mm (1.5in) dia; C01529; Selenium powder [UN2658] [Keep away from food]; Selenium shot, amorphous, 1-5mm (0.04-0.20in); Selenium, foil, 25x25mm, thickness 3mm, 99.95%; Hydrogen selenide, anhydrous [UN2202] [Poison gas]; S008000000; Selenium, plasma standard solution, Specpure, Se 10g/ml; Selenium, shots, 99.99999% (7N), diameter 2-4 mm; Selenium, AAS standard solution, Specpure?, Se 1000?g/ml; Selenium, ingot, 99.9999% diameter 20 mm, length 55 mm; Selenium, pellets, <5 mm, >=99.99% trace metals basis; Selenium, powder, -100 mesh, >=99.5% trace metals basis; Selenium, powder, -100 mesh, 99.99% trace metals basis; Selenium, plasma standard solution, Specpure?, Se 1000?g/ml; Selenium, ingot, 99.99999% (7N), diameter 20 mm, length 55 mm; Selenium, Oil based standard solution, Specpure?, Se 1000?g/g; Selenium, plasma standard solution, Specpure?, Se 10,000?g/ml; Selenium compound, n.o.s. [UN3283] [Poison, Keep away from food]; Selenium, lump, 3 mm max. lump size, weight 100 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 20 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 50 g, high purity 99.999%; Selenium, pellets, <5 mm particle size, >=99.999% trace metals basis; Selenium shot, amorphous, 2-6mm (0.08-0.2in), Puratronic(R), 99.999% (metals basis); Selenium, powder, 250 max. part. size (micron), purity 99.95%, weight 100 g; Selenium, powder, 250 max. part. size (micron), weight 50 g, purity 99.95%; Selenium, powder, max. particle size 250 micron, weight 200 g, purity 99.95%; Se0; Selenium atomic spectroscopy standard concentrate 1.00 g Se, 1.00 g/L, for 1L standard solution, analytical standard
Click to Show/Hide
|
||||
Disease | Thyroid cancer [ICD-11: 2D10] | Phase 4 | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
Se
|
||||
PubChem CID | |||||
Canonical SMILES |
[Se]
|
||||
InChI |
1S/Se
|
||||
InChIKey |
BUGBHKTXTAQXES-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 7782-49-2
|
||||
ChEBI ID | |||||
Herb ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Docetaxel | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
Experimental
Result(s) |
The combination of selenium with docetaxel inhibits cell proliferation through apoptosis and cell arrest in the G2/M phase in MDA-MB-231 breast cancer cells. | |||||
Sulfamethoxazole | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vivo Model | This experiment was carried out on 30 Wistar rats weighing 100-125 g, liver cancer was induced by a carcinogenic dose of 200 mg/kg body weight, I.P. DENA when associated with fasting/refeeding. | |||||
Experimental
Result(s) |
Selenium and sulfonamide (sulfamethoxazole) together can possess synergistic chemopreventive action. | |||||
Levothyroxine | Hypo-thyroidism | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vivo Model | Clinical Trial | |||||
Experimental
Result(s) |
Levothyroxine and selenium combination results in improved therapeutic effects than the levothyroxine monotherapy in preventing CLT progression. | |||||
Ionizing radiation | Renal Insufficiency | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
WI-38 | CVCL_0579 | Healthy | Homo sapiens | |||
Experimental
Result(s) |
Selenium selectively enhanced the radiosensitivity of the tumor cells whereas that of the normal cells was unaffected. | |||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | T84 | CVCL_0555 | Colon adenocarcinoma | Homo sapiens | ||
Caco-2 | CVCL_0025 | Colon adenocarcinoma | Homo sapiens | |||
Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
Rh2 | CVCL_A460 | Embryonal rhabdomyosarcoma | Homo sapiens | |||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | |||
BCaP-37 | CVCL_0164 | Breast cancer | Homo sapiens | |||
LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
MCF-10 | Breast cancer | Homo sapiens | ||||
Experimental
Result(s) |
Supplementation of Selenium enhanced chemotherapeutic effect of Taxol and Doxorubicin in these cells beyond that seen with the chemotherapeutic drugs used alone. | |||||
β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
Cis-diamminedichloroplatinum | Ovarian cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | MC B6-1 cells dissociated from solid tumor | Fibrosarcoma | Rattus norvegicus | |||
In-vivo Model | The MC B6-1 fibrosarcoma was originally induced by s.c.injection of 2 mg of methylcholanthrene in a female C57BL/6 mouse and serially transplanted in syngeneic mice. | |||||
Experimental
Result(s) |
The addition of selenium decreases the nephrotoxicity of cis-DDP. |